查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1579292

女性健康诊断药物市场：按类型、应用和最终用户划分 - 全球预测 2025-2030

Women's Health Diagnostics Market by Type (Point-of-Care, Self Check), Application (Breast Cancer Testing, Cervical Cancer Testing, Infectious Disease Testing), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年女性健康诊断市场价值为433.6亿美元，预计到2024年将达到468.2亿美元，复合年增长率为9.25%，到2030年将达到805.9亿美元。

女性健康诊断市场专注于诊断工具和技术，旨在检测和管理女性特有或不成比例的健康状况，例如乳癌、骨质疏鬆症和生殖健康问题，这是医疗保健中至关重要的部分。对此类诊断的需求源于对及时、准确检测的需求，这对于有效治疗和管理此类疾病至关重要。应用包括早期癌症检测、产前检测、不孕症诊断和一般健康监测。最终用途包括医院、诊断实验室、居家医疗和专门从事妇女健康的专科诊所。

主要市场统计
基准年[2023] 433.6亿美元
预测年份 [2024] 468.2亿美元
预测年份 [2030] 805.9亿美元
复合年增长率（%） 9.25%

影响市场成长的关键因素包括对女性健康意识的提高、微创测试和照护现场诊断等诊断程序的技术进步以及政府加强医疗基础设施的支持政策。此外，慢性病盛行率的上升和对个人化医疗的需求不断增长正在推动市场扩张。整合人工智慧和机器学习以提高诊断准确性，以及开发优先考虑便利性和隐私的家庭诊断工具也存在商机。企业应专注于扩大新兴市场的准入，并与政策制定者合作，提高意识和负担能力。

儘管存在这些充满希望的机会，但仍存在一些挑战，包括与先进诊断相关的高成本、监管障碍以及可能限制低收入地区市场渗透的医疗保健机会差异。此外，维护资料隐私和管理复杂的报销系统是主要障碍。

我们可以透过开发具有成本效益的诊断解决方案和投资研究来增强疾病特异性生物感测器和生物标记来推进研究和开发。此外，利用远端医疗服务涵盖服务不足的人可以创造更广泛的市场进入。综观市场格局，技术快速进步驱动的竞争格局，要求企业在研发投资上保持敏捷和进取。整体而言，女性健康诊断市场具有巨大的成长潜力，但要抓住这个市场需要将策略重点放在创新、可负担性和可近性。

市场动态：快速发展的女性健康诊断市场的关键市场洞察

供需的动态交互作用正在改变女性健康诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 女性慢性病和文明病增加
    • 全球诊断成像中心数量增加
    • 改善且技术先进的医疗保健结构
  • 市场限制因素
    • 与手术和成像系统相关的高成本
  • 市场机会
    • 基于微流体和奈米技术的诊断 POC 设备受到高度关注
    • 有前途的数位科技趋势塑造女性健康检查
  • 市场挑战
    • 技术熟练的医疗保健专业人员短缺

波特五力：驾驭女性健康诊断药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对女性健康诊断药物市场的影响

外部宏观环境因素对女性健康诊断药物市场的绩效动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解女性健康诊断药物市场竞争状况

对女性健康诊断药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 女性健康诊断药物市场定位矩阵供应商绩效评估

FPNV 定位矩阵是评估女性健康诊断市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划女性健康诊断药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对女性健康诊断药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 女性慢性病和文明病增加
      • 世界各地的诊断影像中心不断增加
      • 改善且技术先进的医疗基础设施
    • 抑制因素
      • 与手术和诊断成像系统相关的高成本
    • 机会
      • 专注于基于诊断微流体和奈米技术的 POC 设备
      • 有前景的数位科技趋势塑造女性健康检查
    • 任务
      • 技术熟练的医疗保健专业人员短缺
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 女性健康诊断药物市场：依类型

  • 照护现场
  • 自检

第七章 女性健康诊断药物市场：依应用分类

  • 乳癌检查
    • 切片检查
    • 血液化学测试和血球计数测试
    • 肿瘤标记检测
    • 乳房X光检查
  • 子宫颈癌测试
    • HPV检测
    • 子宫颈抹片
  • 传染病检查
    • 肝炎测试
    • 耐甲氧西林金黄色葡萄球菌测试
    • 结核病测试
    • 尿道感染测试（阴道pH值和阴道炎）
  • 骨质疏鬆测试
    • 骨骼密度测量
    • 体外血液检查
  • 卵巢癌检查
    • 诊断影像检查
    • 卵巢癌肿瘤标记检测
  • 妊娠及不孕症检测
    • 妊娠监测仪
    • 基于实验室的测试
    • 检测套组和排卵预测套件
  • 产前基因筛检和基因带原检测
    • 囊肿纤维化
    • 唐氏症和爱德华兹综合症
    • 火炬感染疾病
  • 性行为感染传染病检测
    • 披衣菌感染衣原体和淋病 (CT/NG) 检测
    • 爱滋病毒检测
  • 超音波检查
    • 乳房摄影诊断
    • 妇产科影像检查诊断

第八章女性健康诊断药物市场：依最终用户分类

  • 诊断/影像诊断中心
  • 居家护理
  • 医院/诊所

第九章 北美和南美女性健康诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太女性健康诊断药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲女性健康诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomerieux SA
  • Cardinal Health, Inc.
  • Carestream Health, Inc.
  • Chembio Diagnostic Systems, Inc.
  • Cook Medical, Inc.
  • Danaher Corporation
  • DIALAB GmbH
  • EKF Diagnostics Holdings PLC
  • F. Hoffmann-La Roche Ltd.
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Guided Therapeutics, Inc.
  • Hill-Rom Holdings, Inc.
  • Hologic, Inc.
  • Koninklijke Philips NV
  • MedGyn Products, Inc.
  • NeuroLogica Corporation
  • Nova Biomedical
  • OSI Systems, Inc.
  • Perkinelmer Inc.
  • Quest Diagnostics Incorporated
  • Sekisui Diagnostics, LLC
  • Siemens AG
  • SuperSonic Imagine
  • Thermo Fisher Scientific Inc.
  • Werfen, SA
Product Code: MRR-43477954269C

The Women's Health Diagnostics Market was valued at USD 43.36 billion in 2023, expected to reach USD 46.82 billion in 2024, and is projected to grow at a CAGR of 9.25%, to USD 80.59 billion by 2030.

The Women's Health Diagnostics market is a pivotal segment within healthcare, focusing on diagnostic tools and techniques aimed at detecting and managing health conditions that uniquely or disproportionately affect women, such as breast cancer, osteoporosis, and reproductive health issues. The necessity for these diagnostics arises from the need for timely and accurate detection, which is crucial for effective treatment and management of such conditions. Applications include early-stage cancer detection, prenatal testing, fertility diagnostics, and monitoring of general well-being. The end-use scope covers hospitals, diagnostic laboratories, home care, and specialized clinics dedicated to women's health.

KEY MARKET STATISTICS
Base Year [2023] USD 43.36 billion
Estimated Year [2024] USD 46.82 billion
Forecast Year [2030] USD 80.59 billion
CAGR (%) 9.25%

Key factors influencing market growth include increasing awareness about women's health, technological advancements in diagnostic procedures like minimally invasive tests and point-of-care diagnostics, and supportive governmental policies enhancing healthcare infrastructure. Additionally, the rising prevalence of chronic diseases and growing demand for personalized medicine are fueling market expansion. Opportunities lie in the integration of AI and machine learning to refine diagnostic accuracy and the development of home-based diagnostic tools that prioritize convenience and privacy. Companies should focus on expanding access in emerging markets and collaborate with policy makers to enhance awareness and affordability.

Despite these promising opportunities, challenges include high costs associated with advanced diagnostics, regulatory hurdles, and disparities in healthcare access, which may limit market penetration in lower-income regions. Additionally, maintaining data privacy and navigating complex reimbursement landscapes pose significant obstacles.

Innovation can be driven by developing cost-effective diagnostic solutions and investing in research to enhance disease-specific biosensors and biomarkers. Furthermore, leveraging telehealth services to reach underserved populations can create broader market access. Insights on market nature indicate a competitive landscape with rapid technological advancements, requiring companies to remain agile and proactive in R&D investments. Overall, the Women's Health Diagnostics market holds substantial growth potential, but capturing it will require strategic focus on innovation, affordability, and accessibility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Women's Health Diagnostics Market

The Women's Health Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incantaces of chronic and life-style related disorders in women
    • Rising number of imaging and diagnostic centres across the globe
    • Improved and technically advanced healthcare infastructure
  • Market Restraints
    • High cost associated with procedure and diagnostic imaging system
  • Market Opportunities
    • Substantial focus on microfluidics and nanotechnology-based POC devices for diagnostic
    • Promising digital technology trends shaping women's health diagnostic
  • Market Challenges
    • Dearth of technically skilled healthcare professionals

Porter's Five Forces: A Strategic Tool for Navigating the Women's Health Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Women's Health Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Women's Health Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Women's Health Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Women's Health Diagnostics Market

A detailed market share analysis in the Women's Health Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Women's Health Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Women's Health Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Women's Health Diagnostics Market

A strategic analysis of the Women's Health Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Women's Health Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux SA, Cardinal Health, Inc., Carestream Health, Inc., Chembio Diagnostic Systems, Inc., Cook Medical, Inc., Danaher Corporation, DIALAB GmbH, EKF Diagnostics Holdings PLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, GE Healthcare, Guided Therapeutics, Inc., Hill-Rom Holdings, Inc., Hologic, Inc., Koninklijke Philips N.V., MedGyn Products, Inc., NeuroLogica Corporation, Nova Biomedical, OSI Systems, Inc., Perkinelmer Inc., Quest Diagnostics Incorporated, Sekisui Diagnostics, LLC, Siemens AG, SuperSonic Imagine, Thermo Fisher Scientific Inc., and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Women's Health Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Point-of-Care and Self Check.
  • Based on Application, market is studied across Breast Cancer Testing, Cervical Cancer Testing, Infectious Disease Testing, Osteoporosis Testing, Ovarian Cancer Testing, Pregnancy & Fertility Testing, Prenatal Genetic Screening & Carrier Testing, Sexually Transmitted Disease Testing, and Ultrasound Tests. The Breast Cancer Testing is further studied across Biopsies, Blood Chemistries & Blood Cell Count Tests, Breast Cancer Tumor Marker Tests, and Mammography. The Cervical Cancer Testing is further studied across HPV Testing and PAP Smear. The Infectious Disease Testing is further studied across HEPAtitis Testing, MRSA Testing, Tuberculosis Testing, and Urinary Tract Infection Testing (Vaginal pH & Vaginitis). The Osteoporosis Testing is further studied across Bone Densitometry and in Vitro Blood Tests. The Ovarian Cancer Testing is further studied across Diagnostic Imaging Tests and Ovarian Cancer Tumor Marker Tests. The Pregnancy & Fertility Testing is further studied across Fertility Monitors, Lab-Based Testing, and Pregnancy Testing & Ovulation Prediction Kits. The Prenatal Genetic Screening & Carrier Testing is further studied across Cystic Fibrosis, Down Syndrome & Edwards Syndrome, and Torch Infections. The Sexually Transmitted Disease Testing is further studied across Chlamydia Trachomatis & Neisseria Gonorrhoeae (CT/NG) Testing and HIV Testing. The Ultrasound Tests is further studied across Breast Imaging and OB/GYN Imaging.
  • Based on End-User, market is studied across Diagnostic & Imaging Centers, Home Care, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incantaces of chronic and life-style related disorders in women
      • 5.1.1.2. Rising number of imaging and diagnostic centres across the globe
      • 5.1.1.3. Improved and technically advanced healthcare infastructure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with procedure and diagnostic imaging system
    • 5.1.3. Opportunities
      • 5.1.3.1. Substantial focus on microfluidics and nanotechnology-based POC devices for diagnostic
      • 5.1.3.2. Promising digital technology trends shaping women's health diagnostic
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of technically skilled healthcare professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Women's Health Diagnostics Market, by Type

  • 6.1. Introduction
  • 6.2. Point-of-Care
  • 6.3. Self Check

7. Women's Health Diagnostics Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer Testing
    • 7.2.1. Biopsies
    • 7.2.2. Blood Chemistries & Blood Cell Count Tests
    • 7.2.3. Breast Cancer Tumor Marker Tests
    • 7.2.4. Mammography
  • 7.3. Cervical Cancer Testing
    • 7.3.1. HPV Testing
    • 7.3.2. PAP Smear
  • 7.4. Infectious Disease Testing
    • 7.4.1. HEPAtitis Testing
    • 7.4.2. MRSA Testing
    • 7.4.3. Tuberculosis Testing
    • 7.4.4. Urinary Tract Infection Testing (Vaginal pH & Vaginitis)
  • 7.5. Osteoporosis Testing
    • 7.5.1. Bone Densitometry
    • 7.5.2. in Vitro Blood Tests
  • 7.6. Ovarian Cancer Testing
    • 7.6.1. Diagnostic Imaging Tests
    • 7.6.2. Ovarian Cancer Tumor Marker Tests
  • 7.7. Pregnancy & Fertility Testing
    • 7.7.1. Fertility Monitors
    • 7.7.2. Lab-Based Testing
    • 7.7.3. Pregnancy Testing & Ovulation Prediction Kits
  • 7.8. Prenatal Genetic Screening & Carrier Testing
    • 7.8.1. Cystic Fibrosis
    • 7.8.2. Down Syndrome & Edwards Syndrome
    • 7.8.3. Torch Infections
  • 7.9. Sexually Transmitted Disease Testing
    • 7.9.1. Chlamydia Trachomatis & Neisseria Gonorrhoeae (CT/NG) Testing
    • 7.9.2. HIV Testing
  • 7.10. Ultrasound Tests
    • 7.10.1. Breast Imaging
    • 7.10.2. OB/GYN Imaging

8. Women's Health Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic & Imaging Centers
  • 8.3. Home Care
  • 8.4. Hospitals & Clinics

9. Americas Women's Health Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Women's Health Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Women's Health Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AccuBioTech Co., Ltd.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Biomerieux SA
  • 6. Cardinal Health, Inc.
  • 7. Carestream Health, Inc.
  • 8. Chembio Diagnostic Systems, Inc.
  • 9. Cook Medical, Inc.
  • 10. Danaher Corporation
  • 11. DIALAB GmbH
  • 12. EKF Diagnostics Holdings PLC
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. FUJIFILM Holdings Corporation
  • 15. GE Healthcare
  • 16. Guided Therapeutics, Inc.
  • 17. Hill-Rom Holdings, Inc.
  • 18. Hologic, Inc.
  • 19. Koninklijke Philips N.V.
  • 20. MedGyn Products, Inc.
  • 21. NeuroLogica Corporation
  • 22. Nova Biomedical
  • 23. OSI Systems, Inc.
  • 24. Perkinelmer Inc.
  • 25. Quest Diagnostics Incorporated
  • 26. Sekisui Diagnostics, LLC
  • 27. Siemens AG
  • 28. SuperSonic Imagine
  • 29. Thermo Fisher Scientific Inc.
  • 30. Werfen, S.A.

LIST OF FIGURES

  • FIGURE 1. WOMEN'S HEALTH DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. WOMEN'S HEALTH DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. WOMEN'S HEALTH DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. WOMEN'S HEALTH DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. WOMEN'S HEALTH DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SELF CHECK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRIES & BLOOD CELL COUNT TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TUMOR MARKER TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HPV TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PAP SMEAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HEPATITIS TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MRSA TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINARY TRACT INFECTION TESTING (VAGINAL PH & VAGINITIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BONE DENSITOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IN VITRO BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TUMOR MARKER TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FERTILITY MONITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LAB-BASED TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING & OVULATION PREDICTION KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DOWN SYNDROME & EDWARDS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TORCH INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS & NEISSERIA GONORRHOEAE (CT/NG) TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OB/GYN IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 263. TAIWAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 275. THAILAND WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & FERTILITY TESTING, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PRENATAL GENETIC SCREENING & CARRIER TESTING, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, 2018-2030 (USD MILLION)
  • TABLE 287. VIETNAM WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OSTEOPOROSIS TESTING, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY & F